secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001213900-24-062226
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences appoints Willis Lee as CEO, eliminates interim Co-President role
--------------------------------------------------------------------------------

- Willis Lee appointed CEO effective July 15, 2024; previously interim Co-President and COO.
- Lee continues as Chairman of the Board (since Oct 2023); compensation unchanged.
- George Sekulich, former interim Co-President, continues as Chief Commercial and Information Officer.
- Move eliminates the interim Co-President structure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024062226/0001213900-24-062226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024062226/ea0209587-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-062226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer